Abstract: GSK126 is a highly selective, S-adenosyl methionine (SAM)-competitive small-molecule inhibitor of the Enhancer of Zeste Homolog 2 (EZH2) methyltransferase, a core catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). While EZH2 overexpression and mutation are heavily implicated in various oncological processes, including diffuse large B-cell lymphoma (DLBCL) and solid tumors, targeting this pathway has presented both therapeutic opportunities and challenges. This review synthesizes current literature on GSK126, detailing its molecular mechanism, pharmacological activity, synthesis, and clinical limitations. Despite promising preclinical efficacy, GSK126 suffers from poor oral bioavailability and limited clinical success, highlighting the need for further optimization and exploration of combination therapies or alternative PRC2 inhibitors.
1. Introduction
Polycomb repressive complex 2 (PRC2) is a critical epigenetic regulator that modulates gene expression and chromatin structure primarily by methylating histone H3 at lysine 27 (H3K27), which leads to gene silencing [1]. The catalytic subunit of PRC2, EZH2, functions as a histone methyltransferase and is frequently mutated or overexpressed in various cancers. Depending on the cellular context, EZH2 can act as both an oncogene and a tumor suppressor [1]. EZH2 hyperactivation is notably prevalent in B-cell lymphomas, such as DLBCL, and various solid tumors, making it a prime target for pharmacological intervention [1]. GSK126 (also known as GSK2816126) was developed as a highly selective inhibitor of EZH2 to counteract these oncogenic processes and has been extensively studied for its therapeutic potential in oncology [1].
2. Pharmacological Activity
In preclinical models, GSK126 demonstrated significant antiproliferative effects. It effectively inhibited the proliferation of EZH2-mutant DLBCL cell lines and showed a 150-fold increased potency toward EZH2 compared to its homolog EZH1 [1]. Furthermore, it exhibited a 1000-fold selectivity for EZH2 over 20 other methyltransferases [1]. In skin cancers, GSK126 significantly increased cell death, reduced epidermal cancer stem cell formation, migration, invasion, and overall tumor growth [1].
A Phase 1 clinical trial (NCT02082977) evaluated GSK126 in patients with refractory non-Hodgkin lymphoma, multiple myeloma, and solid tumors [1]. The trial utilized a dose-escalation strategy up to a maximum dose of 3000 mg. Pharmacokinetic analysis at this dose showed a peak blood concentration (Cmax) of 22 ± 34.1 mg/mL and a half-life (t1/2) of 33.3 ± 11.5 hours [1]. However, out of 22 evaluable patients, only one patient with GC B DLBCL achieved a partial response, while seven had stable disease. The study was ultimately terminated because the drug did not provide sufficient evidence of a meaningful therapeutic effect to warrant further clinical investigation [1].
3. Molecular Mechanism of Action
GSK126 functions as a direct, S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2 [1][2]. EZH2 catalyzes the transfer of methyl groups from the universal methyl donor, SAM, to the lysine 27 residue of histone 3 (H3K27), resulting in transcriptional repression [2]. GSK126 exerts its inhibitory effects by competing with SAM for binding to the SET domain of EZH2 [2]. By blocking this binding site, GSK126 prevents the methylation of H3K27, thereby reversing the epigenetic silencing of target genes. In an oncological context, this mechanism can release tumor suppressor genes from epigenetic repression, halting cancer cell survival and proliferation [1].
4. Structure-Activity Relationship (SAR)
The synthesis and structural assembly of GSK126 have been optimized to improve production feasibility and reduce costs. Retrosynthetic analysis of GSK126 reveals that it is constructed using a halo-indole carboxyl group as a foundational building block [1]. This precursor is joined with a boronate ester, specifically 1-(5-(4,4,5,5-tetramethyl 1,3,2-dioxaborolan-2-yl)-piperazine, through a Suzuki–Miyaura cross-coupling reaction [1]. Subsequently, amide coupling is employed to link the resulting compound with 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone to form the final GSK126 molecule [1]. This specific synthetic route drastically decreased the cost of production, allowing further research on the compound to be feasible [1].
5. Current Limitations
Despite its high selectivity and preclinical promise, GSK126 faces several critical limitations. Foremost is its lack of oral bioavailability, which restricts its clinical utility compared to other EZH2 inhibitors like Tazemetostat or Valemetostat [1]. Clinically, the drug failed to demonstrate sufficient efficacy, with a majority of patients (51%) in the Phase 1 trial experiencing progressive disease [1]. The maximum tolerated dose was established at 2400 mg due to dose-limiting elevated liver transaminases observed at 3000 mg [1]. Frequent adverse side effects included fatigue (53%), nausea (30%), anemia (20%), and vomiting (20%) [1].
Additionally, acquired resistance is a significant hurdle. Activation of the IGF-1R, PI3K, and MEK pathways has been shown to confer resistance to SAM-competitive EZH2 inhibitors like GSK126 [1]. Cells that gain resistance to GSK126 also exhibit cross-resistance to Tazemetostat, complicating sequential therapy options and rendering GSK126 unsuitable for patients suffering from relapses of follicular lymphoma who have already received Tazemetostat [1].
6. Future Perspectives
While GSK126 may not advance as a standalone systemic therapeutic agent in oncology due to its pharmacokinetic and efficacy limitations, it remains a highly valuable in vitro tool for studying EZH2 inhibition and epigenetic regulation [1]. Future research in oncology is pivoting towards dual EZH1/2 inhibitors (such as Valemetostat and UNC1999) or allosteric inhibitors targeting other PRC2 subunits (such as EED or SUZ12) to overcome the resistance mechanisms associated with SAM-competitive EZH2 inhibitors [1]. Furthermore, the role of EZH2 inhibitors is expanding beyond oncology into neuroinflammation and neuropathic pain, where GSK126 has shown potential in ameliorating pain by modulating microglial activation and pro-inflammatory cytokine production [2]. This suggests that GSK126 may find greater relevance in alternative therapeutic fields where EZH2 inhibition is required [1].
